Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vecabrutinib (SNS-062) in B-Lymphoid Malignancies
NCT03037645Phase 2Terminated
- Sponsor
- Sunesis Pharmaceuticals, Inc.
- Start
- Apr 2017
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vecabrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Lymphoplasmacytic Lymphoma (LPL), Waldenstrom macroglobulinemia (WM), mantle cell lymphoma (MCL), sponsored by Sunesis Pharmaceuticals, Inc.. Started Apr 2017; status: terminated.
02
Drugs
vecabrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)Lymphoplasmacytic Lymphoma (LPL)Waldenstrom macroglobulinemia (WM)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03037645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03037645.